Clinical study of autologous tumor lysate-pulsed dendritic cell therapy after resection of lung cancer

Clinical study of autologous tumor lysate-pulsed dendritic cell therapy after resection of lung cancer - Clinical study of autologous tumor lysate-pulsed dendritic cell therapy after resection of lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000005776

Enrollment

Registered

2011-06-14

Start date

2011-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lung cancer

Interventions

1)Tumor lysate-pulsed dendritic cells (biweekly, 6 times) 2)Standard adjuvant chemotherapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Lung cancer patients who received resection of primary lesion: (1)Performance Status is 0-1 (2)No serious abnormality in bone marrow, liver, and renal functions (3)Whose life-expectancy is more than 3 months

Exclusion criteria

Exclusion criteria: Patients who have: (1)Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them (2)Serious drug allergy (3)Serious cardiac disease (4)Active autoimmune disease (5)Other cancers (6)Active infections (7)Positive for HIV or HTLV-1 (8)Other serious complications (9)Pregnant or lactating (10)Continuous systemic administration of steroids (11)Any reason why, in the opinion of the investigator, the patient should not participate.

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Immunological responses Recurrence-free survival Overall survival Survival rate (3 and 5 years) Response of tumor-related markers	—

Countries

Japan

Contacts

Public ContactHiroshi Ibe

Seta Clinic Clinical research center

scrc@j-immunother.com03-5215-0086

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026